Aptinyx plunges after pain drug fails mid-stage trial

Aptinyx

07/04/2022 13:20

** Shares of drug developer  APTX.O  down 51.7% at $1.13
premarket - top pct loser across U.S. exchanges 
    ** Co's experimental drug to treat nerve pain failed to meet
main goal of mid-stage study in patients with painful diabetic
peripheral neuropathy  urn:newsml:reuters.com:*:nBwbFGNdWa
    ** "The data from this study do not currently point to a
path forward in development for painful DPN" - CEO Andy Kidd
    ** Drug NYX-2925 failed to show significant difference
compared to placebo in relieving pain 
    ** Stock down 12.4% this year, as of last close

 (Reporting by Nandhini Srinivasan)
 ((Nandhini.Srinivasan@thomsonreuters.com;))